PDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS

PDS Biotechnology (NASDAQ:PDSB – Get Rating) announced its quarterly earnings data on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.09), MarketWatch Earnings reports. During the same quarter in the previous year, the company earned ($0.14) earnings per share.

NASDAQ PDSB traded up $0.73 on Friday, reaching $4.56. 552,690 shares of the stock traded hands, compared to its average volume of 232,316. PDS Biotechnology has a 12 month low of $3.47 and a 12 month high of $17.85. The firm’s fifty day simple moving average is $5.66 and its 200 day simple moving average is $7.26.

Several analysts recently weighed in on the company. Noble Financial reissued a “buy” rating and issued a $22.00 price objective on shares of PDS Biotechnology in a report on Thursday. Zacks Investment Research cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. StockNews.com upgraded PDS Biotechnology to a “sell” rating in a research report on Saturday, April 9th. Finally, Alliance Global Partners dropped their price target on PDS Biotechnology from $18.00 to $16.00 in a research report on Friday. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $17.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PDSB. Renaissance Technologies LLC grew its stake in PDS Biotechnology by 49.5% during the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock valued at $4,117,000 after acquiring an additional 220,300 shares in the last quarter. Vanguard Group Inc. grew its stake in PDS Biotechnology by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 1,093,885 shares of the company’s stock valued at $6,771,000 after acquiring an additional 79,025 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in PDS Biotechnology by 99.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 69,628 shares of the company’s stock valued at $431,000 after acquiring an additional 34,797 shares in the last quarter. BlackRock Inc. grew its stake in PDS Biotechnology by 1.0% during the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock valued at $2,697,000 after acquiring an additional 4,199 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in PDS Biotechnology by 78.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the company’s stock valued at $155,000 after acquiring an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 20.94% of the company’s stock.

PDS Biotechnology Company Profile (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

See Also